D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Key Points

• D. Boral Capital has reiterated a buy rating for Coya Therapeutics (NASDAQ:COYA) with a price target of $18.00, suggesting a potential upside of 169.66% from its previous close.
• Despite the positive ratings from several firms, Coya Therapeutics reported a loss of $0.36 per share for the last quarter, missing analysts' expectations.
• 39.75% of Coya Therapeutics' stock is owned by institutional investors, with notable increases in holdings from firms like DME Capital Management LP and Jane Street Group LLC.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $18.00 price objective on the stock. D. Boral Capital's price objective points to a potential upside of 169.66% from the company's previous close.

COYA has been the subject of several other research reports. Lake Street Capital assumed coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They set a "buy" rating and a $16.00 price target for the company. Chardan Capital restated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. Finally, Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Coya Therapeutics has a consensus rating of "Buy" and a consensus price target of $16.50.

Coya Therapeutics Trading Down 0.2%

Shares of COYA opened at $6.68 on Thursday. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24. The company has a market cap of $111.67 million, a PE ratio of -5.38 and a beta of 0.26. The stock has a 50-day moving average price of $6.19 and a 200-day moving average price of $6.08.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The firm had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.78 million. As a group, analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in COYA. DME Capital Management LP grew its holdings in shares of Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after acquiring an additional 372,414 shares in the last quarter. Dauntless Investment Group LLC bought a new position in Coya Therapeutics in the first quarter valued at approximately $1,083,000. CM Management LLC increased its holdings in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after buying an additional 40,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Coya Therapeutics during the 2nd quarter worth about $119,000. Finally, Jane Street Group LLC raised its stake in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after buying an additional 13,176 shares during the period. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.